Business Context and Reporting Period
This Form 8-K filing by Pharmacyte Biotech, Inc. (Nevada corporation) reports a corporate governance event dated July 3, 2017, with the report filed on July 7, 2017. The filing addresses the appointment of a new director to fill a vacancy created in October 2014.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The only financial figures disclosed relate to the compensation package for the newly appointed director:
- Quarterly Cash Retainer: $12,500 per calendar quarter.
- Annual Equity Grant: 500,000 restricted common shares.
- Annual Option Grant: 500,000 shares with a five-year term.
- Option Exercise Price: $0.058 per share (fair market value on grant date).
- Vesting Status: Shares and options were fully vested on the date of grant.
Material Changes
The material change reported is the appointment of Michael M. Abecassis, M.D., to the Board of Directors. This appointment fills a long-standing vacancy and introduces a new compensatory arrangement involving significant equity issuance (1,000,000 shares total between stock and options annually).
Guidance, Outlook, and Risks
The filing contains no management guidance, financial outlook, or discussion of operational risks. The document includes a Regulation FD disclosure referencing a press release regarding the appointment. The filing notes that the description of the Director Agreement is qualified by reference to the full text filed as Exhibit 10.1.
Investor Verification Checklist
- Verify the total number of shares outstanding post-issuance to assess dilution impact from the 500,000 share grant and 500,000 option grant.
- Review the full text of the Director Agreement (Exhibit 10.1) for additional terms not summarized in the 8-K.
- Confirm the current fair market value of the stock relative to the $0.058 exercise price to evaluate the intrinsic value of the option grant.
- Check subsequent filings for the actual issuance date of the restricted shares and options.